IMCAS 2025：高德美发布塑妍萃® 等美学产品最新数据，再次彰显行业领导地位

·作为首款经过验证的原研注射用聚左旋乳酸填充剂，塑妍萃^®的新数据强调了其对所有三层皮肤组织的产生疗效，并与其他生物刺激剂进行了对比，进一步突出其独特效果。^8-12

·高德美将发布关于新型液态A型肉毒毒素（RelabotulinumtoxinA）的新数据。这是首款且唯一一款通过 PEARL™技术研发的即用型液态肉毒毒素，目前已在欧洲多个国家和地区上市。本次数据包括 IIIb 期 RELAX 试验的结果，进一步证明了其长期疗效和高患者满意度，这一成果也在 READY 临床试验项目中得到过验证^1-7

·瑞蓝系列产品的最新数据突出了其在保持面部表情自然性方面的卓越能力，并揭示了由高德美创新 NASHA HD™技术驱动的新型透明质酸（HA）注射产品瑞蓝 SHAYPE（尚未于中国大陆地区上市）在常用 HA 填充剂中拥有最高的 G’值^13,14

·这些数据结合三场专题研讨会、一场关于药物引起的体重减轻对皮肤美学影响的大师班，以及多场“专家见面会”，再次展示并凸显了高德美广泛且经临床验证的产品组合，进一步确立了其作为皮肤学领域的专业领导地位

近日，高德美将在2025年英卡思国际整形美容暨皮肤抗衰老医学大会（IMCAS）上展示其创新美学产品组合的最新进展。大会将于1月30日至2月1日在法国巴黎举行。高德美将分享十项研究电子海报，展示其注射型美学产品的差异化数据，包括新型液态A型肉毒毒素（RelabotulinumtoxinA）、塑妍萃^®和瑞蓝系列。此外，高德美还将与合作伙伴共同举办三场专题研讨会、一场大师班、五场“专家见面会”，并设立互动展位，重点展示新型液态A型肉毒毒素的强大优势。

“今年在 IMCAS 大会上的广泛参与，让我们有机会不仅展示我们广泛而创新的注射美学产品组合的最新进展，同时通过信息共享和见解交流，与行业各界进行有意义的互动。我们在 IMCAS 的活动充分体现了我们的综合皮肤学战略，凸显了产品优势，同时巩固了高德美作为肤学领域的领导者地位。”高德美全球研发负责人、医学博士、哲学博士Baldo Scassellati Sforzolini表示。

行业广泛注射美学产品组合的最新数据更新

高德美将发布关于塑妍萃^®的最新数据。塑妍萃^®是全球首款原研注射用聚左旋乳酸填充剂，采用独特的PLLA-SCA™（聚左旋乳酸）配方。^8-12最新数据显示，PLLA-SCA™（聚左旋乳酸）具有强大的再生特性，并能对皮肤三层结构起作用，突出其在再生美学领域的关键地位，包括其与其他产品相比的优势。^19-21研究表明，塑妍萃^®能刺激皮肤中的关键成分，包括胶原蛋白、弹性蛋白和脂肪组织。同时强调了其良好的安全性。^19-21另一项比较研究发现，将塑妍萃^®与 Alastin^® 联合用于中面部，能产生协同效果，对抗衰老皮肤并提升患者体验。²²

最新数据还将包含 IIIb 期 RELAX 研究的成果。该研究调查了新型液态A型肉毒毒素在单剂量治疗后长达12 个月内对中重度眉间纹的长期美学改善及患者满意度。这项研究进一步支持了先前 READY 临床试验项目的数据，显示高达39%新型液态A型肉毒毒素治疗时，高达 39% 的患者从第一天起就看到效果，高达 75% 的患者在治疗眉间纹和鱼尾纹后可在六个月内维持改善。^3,4,7

其他研究数据将进一步凸显新型液态A型肉毒毒素的科学优势，包括高德美专利 PEARL^TM 技术对分子完整性的保护作用，以及在新型液态A型肉毒毒素的 III 期试验重未发现中和抗体的形成。^16,17此外，将发布来自 READY - 1 - 3 试验的汇总事后分析，分析涵盖1700多名具有不同肤色、种族和民族背景的患者，进一步验证了新型液态A型肉毒毒素的疗效。¹⁸

此外，一场主题为“超越 Relfydess：引领未来”的专题研讨会将于欧洲中部时间1月 31日（星期五）下午 2:00至3:30在 Grand Amphi 举行，会上将展示新型液态A型肉毒毒素的临床表现和创新的容积注射方法，并进行现场注射演示。在高德美展位（#L212），专家还将深入探讨新型液态A型肉毒毒素背后的前沿科学与PEARL^TM技术。

高德美还将公布三项关于瑞蓝系列产品的新汇总数据，显示使用瑞蓝· Refyne™（尚未于中国大陆地区上市）和瑞蓝·定采^®进行治疗不仅能提升面部吸引力和年轻感，还能在面部静态和动态表情保持自然感。²³此外，作为高德美透明质酸（HA）产品组合中的新成员，瑞蓝 SHAYPE 的凝胶数据也将首次亮相。瑞蓝 SHAYPE采用高德美创新的 NASHA HD 技术，具备更高的交联效率和更高的 HA 含量,数据显示其G’值为现有 HA 填充剂中最高，表明其凝胶强度和硬度更优，非常适合用于下面部塑形。¹⁴

与皮肤病学界的交流互动

除了分享最新数据，IMCAS 世界大会也是与更广泛的皮肤病学界建立联系的重要机会，旨在促进最佳实践的交流并收集关键见解，为未来的创新提供指导。高德美的全球美学注射医师网络（GAIN）今年迎来了其10 周年庆典，作为高德美长期设立的全球交流平台，GAIN旨在通过创建一个由临床经验丰富的美学从业者组成的独特社区，为其提供交流、启发和赋能。

作为这一持续承诺的一部分，高德美将在大会上举办一场题为“GAIN 辩论：塑造我们的美学人生——聚焦有影响力的治疗”的专题研讨会，该研讨会将于欧洲中部时间 1 月 31 日（星期五）上午 10:30至12:30在 Amphi Bleu 举行。另一场主题为 “高德美创新：美学与科学的交汇” 的医学专题研讨会也将于欧洲中部时间 1 月 31 日（星期五）上午 9:00 至10:00在 4 楼 Regency 3 + 4 举行。

高德美还将举办一场关于注射剂使用的大师班课程，讨论如何应对药物引起的体重减轻对美学的具体需求。该课程将于欧洲中部时间1 月 30 日（星期四）下午 2:00至4:00在 Salon d’honneur举行。同时，五场“专家见面会”将进一步巩固高德美作为皮肤学领域领导者的独特地位。会议将探讨包括皮肤质量、全程胶原蛋白和弹性蛋白刺激，以及重新定义透明质酸（HA） 填充剂以创新自然效果的主题，并深入探讨 Alastin^®、塑妍萃^®和新型液态A型肉毒毒素等产品。这些活动将在高德美展台举行，并将在 @GAINbyGalderma Instagram 账号上进行直播。

说明：瑞蓝 SHAYPE、瑞蓝· Refyne™尚未于中国大陆地区上市

References

参考资料

1.Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting

2.Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA

3.Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. ASJ. 2024; sjae131

4.Ablon G, et al. Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study. Dermatol Surg. 2024. doi: 10.1097/DSS.0000000000004470

5.Prather HB, et al. Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines. E-poster presented at: ASDS 2024; October 17-20, 2024; Orlando, Florida, United States

6.Beer K, et al. READY-4: Long-term safety with repeated injections using RelabotulinumtoxinA, a novel liquid formulation botulinum toxin, in the treatment of glabellar and lateral canthal lines. E-poster presented at: ASDS 2024; October 17-20, 2024; Orlando, Florida, United States

7.Relfydess^®. EU Summary of Product Characteristics

8.Sculptra^®. EU Instructions for Use. 2021. Available online. Accessed January 2025

9.Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France

10.Galderma. Data on File (MA-60875)

11.Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042

12.Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791

13.Philipp-Dormston, W.G., Wong, C., Schuster, B., Larsson, M.K. and Podda, M., 2018. Evaluating perceived naturalness of facial expression after fillers to the nasolabial folds and lower face with standardized video and photography. Dermatologic Surgery, 44(6), pp.826-832.

14.Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

15.Moradi A, et al. Aesthetic improvement and subject satisfaction with liquid relabotulinumtoxinA treatment of glabellar lines in a 12-month, randomized, controlled trial. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France

16.Lekholm E, et al. RelabotulinumtoxinA, a ready-to-use formulation neuromodulator manufactured with PEARL™ technology to maintain high potency and specific activity. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

17.Nestor M, et al. RelabotulinumtoxinA did not induce the formation of neutralizing antibodies across almost 1700 subjects treated in the Phase III Program. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

18.Bertucci V, et al. Treatment of Glabellar Lines and Lateral Canthal Lines with RelaBoNT-A Across Different Ethnicity and Race: Pooled Data from Three Phase III Studies. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

19.Fabi S, et al. Regenerative aesthetic effects of poly L-lactic acid (Sculptra^®) treatment. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

20.Haddad A, et al. Comparing poly L-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA-R) in-vivo. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

21.Avelar L, et al. Comparing two biostimulators on the local tissue response and degradation in-vivo with an indirect comparison to clinical outcomes. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

22.Markowitz O, et al. Evaluation of synergistic effects for midface improvement when pairing Sculptra^® (PLLA-SCA) with Alastin skincare^®: A comparative study. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

23.Nikolis A, et al. Hyaluronic acid fillers preserve natural movement and dynamic expression: data from three Phase IV clinical trials. Abstract presented at IMCAS World Congress, January 30 – February 1, 2025, Paris, France.

24.Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin

25.U.S. Food and Drug Administration. Sculptra summary of safety and effectiveness data. Available online. Accessed January 2025.

26.Galderma. Data on File (MA-46589)

27.Duracinsky M, et al. Safety of poly-L-lactic acid (New-Fill^®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis. 2014;14(474). doi:10.1186/1471233414474

28.Zhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transpl. 2018;27(5):729-738. doi: 10.1177/0963689717725755

29.Asius J, et al. Inventors. US patent US 7,731,758 B2.2010. Available online. Accessed January 2025

30.Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress, January 26–28, 2023, Paris, France

31.Galderma. Data on File (MA-53568)

32.Shuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. Br J Dermatol. 1975;93(6):639-43. doi: 10.1111/j.1365-2133.1975.tb05113.x

33.Goldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39:915–22

34.Zarbafian M, et al. The emerging field of regenerative aesthetics—where we are now. Dermatol Surg. 2022;48: 101–108. doi: 10.1097/DSS.0000000000003239

35.Waibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024, October 17-20, 2024, Orlando, Florida, United States

36.Waibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapetite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting, October 17-20, 2024, Orlando, Florida, United States

37.Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022;61:1284–1288. doi: 10.1111/ijd.16229

38.Vleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44–s51

39.Hexsel D, et al. Introducing the L-Lift-A Novel Approach to Treat Age-Related Facial Skin Ptosis Using A Collagen Stimulator. Dermatol Surg. 2020;46(8):1122–1124. doi:10.1097/DSS.0000000000002015

40.Fabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC, March 30 - April 1, 2023, Monaco

41.Di Gregorio C. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC, March 27-29, 2024, Monaco

42.Nikolis A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12.

43.Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021

44.Restylane U.S. Instructions For Use. Available online. Accessed January 2025.

45.Kablik J, et al. Comparative Physical Properties of Hyaluronic Acid Dermal Fillers: Dermatologic Surgery 35, 302–312 (2009).

46.Narins RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650

47.Talarico S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369

48.Ohrlund A, et al.. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. JDD. 2024; 23(1), pp.1332-1336.

49.Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-46.

50.Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-6.